Dr Sujit Nair speaks to ecancer about a trial investigating neoadjuvant poly-ICLC for prostate cancer.

Poly-ICLC is a double-stranded RNA that mimics viral activity, thereby stimulating the immune response.

The trial used a dose escalation strategy in 12 patients diagnosed with clinically localised prostate cancer with plans for surgery.

The trial demonstrates the feasibility of intratumoral immunotherapy for prostate cancer using the investigational agent poly-ICLC.

Treatment with poly-ICLC reliably transforms the cold microenvironment of prostate cancer into a hot, immune-enhanced ecosystem.